Although there has been a steady strategic decline in epilepsy research within the pharmaceutical industry over recent years, here at Transpharmation we still conduct preclinical epilepsy screens to support niche drug discovery programmes and therapeutic index assessment of NCEs regularly. Also, since many compounds demonstrating efficacy in pain assays are also anti-epileptic, our epilepsy models are often used as a rapid PD screen or novel analgesics prior to evaluation in more complex neuropathic pain assays.

All our epilepsy models are well-validated with clinical gold standards such as lamotrigine, diazepam and carbamazepine. Routine plasma/tissue sample collection verifies the establishment of PK/PD relationships.

Examples of the models we offer include the following:

  • Electrically induced seizures, e.g. MES, MEST, minEST
  • Chemically evoked seizures, e.g. kainate, pentylenetetrazol
  • Telemeterised EEG monitoring of brain seizure activity
  • Detailed scoring of behavioural seizures according to Racine’s scale
  • Concomitant assessment of therapeutic index utilising rotarod and LABORAS
  • Identification of additional therapeutic utilities of novel anticonvulsants e.g. for treatment of neuropathic pain.

epilepsyThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

uk flag +44 (0)20 7691 0984

ireland flag +353 (0)1896 42 60

mail contact@transpharmation.co.uk


Copyright © 2020 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design


The first International Association for the Study of Pain, (IASP) virtual conference is live!

Come and visit Transpharmation’s booth #iaspvirtualseries

View our latest specialist poster on pain; ‘The effect of a reduced streptozocin dose and social housing on well-being, mechanical hypersensitivity and burrowing behaviour in type 1 diabetic rodents’ and find out more about our wide-ranging pain expertise.  We look forward to seeing you there.

IASP Footer